| 0 (0%) | 02-21 18:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 130.34 | 1-year : | 140.52 |
| Resists | First : | 111.59 | Second : | 120.31 |
| Pivot price | 106.71 |
|||
| Supports | First : | 97.48 | Second : | 81.11 |
| MAs | MA(5) : | 105.82 |
MA(20) : | 108.43 |
| MA(100) : | 90.2 |
MA(250) : | 49.68 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 43.4 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 120.31 | Low : | 7.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CELC ] has closed above bottom band by 29.4%. Bollinger Bands are 47.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 107.33 - 107.86 | 107.86 - 108.29 |
| Low: | 101.56 - 102.27 | 102.27 - 102.84 |
| Close: | 103.79 - 104.87 | 104.87 - 105.75 |
Fri, 20 Feb 2026
Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews
Sun, 15 Feb 2026
What Celcuity (CELC)'s Board Addition of Veteran Oncology Executive Means For Shareholders - Yahoo Finance
Fri, 13 Feb 2026
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Fri, 13 Feb 2026
Is Celcuity’s New Oncology Commercial Leader Appointment Reshaping the Investment Case for CELC? - Sahm
Thu, 12 Feb 2026
Ex-Seagen oncology exec joins Celcuity board for breast cancer drug push - Stock Titan
Thu, 12 Feb 2026
Discipline and Rules-Based Execution in CELC Response - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 46 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 10.9 (%) |
| Held by Institutions | 86.9 (%) |
| Shares Short | 9,130 (K) |
| Shares Short P.Month | 7,320 (K) |
| EPS | -3.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.7 % |
| Return on Equity (ttm) | -122.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -145 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -29.19 |
| PEG Ratio | 0 |
| Price to Book value | 38.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -33.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|